Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond-Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit erythroid progenitors (CFU-Es) that respond to Epo are either too few in number or are not sensitive enough to Epo to maintain sufficient red blood cell production [1] [2] [3] [4] [5] [6] [7] [8] [9] . Treatment of these anaemias requires a drug that acts at an earlier stage of red cell formation and enhances the formation of Epo-sensitive CFU-E progenitors. Recently, we showed that glucocorticoids specifically stimulate self-renewal of an early erythroid progenitor, burst-forming unit erythroid (BFU-E), and increase the production of terminally differentiated erythroid cells 10, 11 . Here we show that activation of the peroxisome proliferator-activated receptor a (PPAR-a) by the PPAR-a agonists GW7647 and fenofibrate synergizes with the glucocorticoid receptor (GR) to promote BFU-E self-renewal. Over time these agonists greatly increase production of mature red blood cells in cultures of both mouse fetal liver BFU-Es and mobilized human adult CD34 1 peripheral blood progenitors, with a new and effective culture system being used for the human cells that generates normal enucleated reticulocytes. Although Ppara 2/2 mice show no haematological difference from wild-type mice in both normal and phenylhydrazine (PHZ)-induced stress erythropoiesis, PPAR-a agonists facilitate recovery of wildtype but not Ppara 2/2 mice from PHZ-induced acute haemolytic anaemia. We also show that PPAR-a alleviates anaemia in a mouse model of chronic anaemia. Finally, both in control and corticosteroid-treated BFU-E cells, PPAR-a co-occupies many chromatin sites with GR; when activated by PPAR-a agonists, additional PPAR-a is recruited to GR-adjacent sites and presumably facilitates GR-dependent BFU-E self-renewal. Our discovery of the role of PPAR-a agonists in stimulating self-renewal of early erythroid progenitor cells suggests that the clinically tested PPAR-a agonists we used may improve the efficacy of corticosteroids in treating Epo-resistant anaemias.
The therapeutic effect of glucocorticoids in treating Epo-resistant anaemias such as Diamond-Blackfan anaemia (DBA) is well documented, although steroid therapy has severe side effects that limit its use 12, 13 . Given the physiological importance and attractive drug targets of nuclear receptors (NRs) [14] [15] [16] [17] , and in the hope of identifying other small-molecule drugs that can either individually or in combination with glucocorticoids expand BFU-E progenitors, we analysed the expression of 49 NR genes during mouse BFU-E self-renewal promoted by dexamethasone (DEX) 10 . Although the expression of most NR genes was unchanged, seven were upregulated and three downregulated by more than twofold ( Supplementary Table 1 ). Among these, PPAR-a changed the most: a fivefold induction (Extended Data Fig. 1a ). While most NR agonists and antagonists had no significant effects on erythroid production in cultures of primary mouse BFU-Es, two PPAR-a agonists, GW7647 and fenofibrate, synergized with DEX to increase the output of erythroid cells (Supplementary Table 2 and Fig. 1a ). In the absence of corticosteroids, neither GW7647 nor fenofibrate affected erythropoiesis. Fenofibrate is a US Food and Drug Administration (FDA)-approved drug primarily used to treat hypercholesterolaemia and hypertriglyceridaemia 18 , and GW7647 is a PPAR-a agonist with higher receptor binding affinity and specificity (half-maximum effective concentration (EC 50 ) 5 6 nM) 19 .
When added together with DEX, either GW7647 or fenofibrate led to a ,150-fold increase in erythroblast production, 3-5-fold greater than DEX alone ( Fig. 1a ). At the end of the culture, virtually all of the cells were erythroblast cells (Extended Data Fig. 1b ). Importantly, the expression of Ppara declines markedly from the BFU-E to the CFU-E stage, consistent with the decline of DNase I hypersensitivity of the Ppara promoter (Extended Data Fig. 1c, d) .
Neither GW7647 nor fenofibrate were able to increase erythroblast production from isolated mouse CFU-E cells, suggesting a specific function of PPAR-a agonists on BFU-Es (Extended Data Fig. 1e ). GW7647 also synergized with lower doses of DEX in promoting erythroid cell production ( Fig. 1b) . Importantly, the effects of GW7647 and fenofibrate require the PPAR-a receptor, since BFU-E cells isolated from Ppara 2/2 mice 20 failed to respond to their treatment ( Fig. 1a ).
Added together with DEX, 10 mM of either GW7647 or fenofibrate significantly increased BFU-E colony numbers and maintained high BFU-E numbers over one additional day relative to that achieved by DEX alone (Fig. 1c ). Concentrations of GW7647 as low as 100 nM effectively synergized with 100 nM DEX in promoting BFU-E selfrenewal (Extended Data Fig. 1f ).
Blood from Ppara 2/2 mice exhibits no haematological abnormalities, indicating that PPAR-a is not necessary for normal erythropoiesis (Supplementary Table 3 ). Consistent with this, the PPAR-a antagonist GW6471 does not interfere with DEX-promoted BFU-E selfrenewal, indicating that DEX does not promote BFU-E self-renewal through activating the transcriptional activity of PPAR-a (Extended Data Fig. 1g ).
Adding GW7647 increases total cell number by an additional fourfold, yielding a 120,000-fold expansion in our newly developed synchronized human CD34 1 erythroid culture system (Supplementary Discussion and Fig. 2a ). In these cultures the numbers of BFU-Es and CFU-Es are highest during days 5-8 ( Fig. 2b and Extended Data Fig. 2a ). Addition of GW7647 with DEX increased total BFU-E numbers, which in turn subsequently increased total CFU-E numbers in the culture. Similar to mouse BFU-E cultures, GW7647 synergized with very low concentrations of DEX in stimulating erythroid expansion of human CD34 1 cells (Extended Data Fig. 2b ). Addition of DEX and GW7647 affects expression of many key erythroid genes (Supplementary Discussion).
As expected, knocking down PPAR-a abrogated the ability of GW7647 to stimulate production of BFU-E cells or the total number of erythroid cells at the end of the culture ( Fig. 2c and Extended Data Fig. 2c ). Consistent with the absence of a role for PPAR-a in normal haematopoiesis, knocking down PPAR-a in human CD34 1 cells did not affect the ability of DEX to stimulate BFU-E production or production of erythroid cells. Thus, in the human as well as in the mouse, only ligand-activated, not unactivated, PPAR-a synergizes with GR to promote BFU-E self-renewal during erythroid differentiation. We note that our cultures are highly synchronous on the basis of cell surface marker expression (Extended Data Fig. 2e ) as well as morphology ( Fig. 2d ). Neither DEX nor GW7647 had any effects on terminal differentiation or enucleation (Extended Data Fig. 2h) .
GW7647 significantly increased the number of both BFU-E and CFU-Es in our CD34 1 cell culture system after RPS19 knockdown, which recapitulates RPS19 haploinsufficiency in DBA patients 21, 22 (Extended Data Fig. 3a ). Addition of GW7647 substantially increased the fraction of CD71 1 cells at day 9 of culture after RPS19 knockdown as well as total cell numbers and the fraction of CD235a 1 cells at day 21 (Extended Data Figs 3b, c). Taken together, our data suggest that GW7647 facilitates BFU-E self-renewal and production of immature erythroid progenitors in both wild-type and RPS19-knockdown human cells.
We next tested the function of GW7647 in a PHZ-induced haemolytic anaemia mouse model in which the endogenous corticosteroid level becomes markedly increased 11 . Wild-type mice were treated with either dimethylsulfoxide (DMSO) or GW7647 for 3 days followed by treatment with PHZ; they were then injected with DMSO or GW7647 for another 7 days (Supplementary Discussion and Extended Data Fig.  4a ). Treatment with GW7647 resulted in significantly higher levels of haemoglobin, red blood cell numbers, and haematocrit after PHZ injection compared to in control mice ( Fig. 3a) . In contrast, white blood cell counts were similar in the two groups (data not shown). Importantly, the function of GW7647 during stress erythropoiesis was dependent on PPAR-a, as Ppara 2/2 mice failed to respond to GW7647 treatment (Extended Data Fig. 4b ).
We also tested the ability of PPAR-a agonists to stimulate red cell production in a mouse model of chronic anaemia, 'neonatal anaemia' (Nan) mice (Supplementary Discussion). While BFU-E numbers in spleens of Nan/1 mutant mice are similar to or slightly higher than that in wild-type mice, the average number of BFU-Es in the spleens of GW7647-injected Nan/1 mutant mice are higher than that in untreated mice (Extended Data Fig. 5b ). Importantly, GW7647 injection increased haemoglobin level, haematocrits and red blood cell numbers in these anaemic mice ( Fig. 3b ), suggesting that the PPARa agonist alleviates anaemia in Nan/1 mutant mice by increasing BFU-E numbers in the spleen. GW7647 does not have any significant effects on either platelet or white blood cell numbers in peripheral blood from Nan/1 mice (Extended Data Fig. 5c ).
To understand the molecular mechanism by which PPAR-a synergizes with GR to promote BFU-E self-renewal, we conducted chromatin immunoprecipitation followed by sequencing (ChIP-seq) Figure 1 | PPAR-a signalling synergizes with GR to promote self-renewal of mouse BFU-E erythroid progenitors. a, Wild-type (WT; left) and Ppara 2/2 (right) BFU-E cells from embryonic day (E)14.5 mouse fetal livers were isolated and cultured in serum-free erythroid liquid expansion (SFELE) medium with the indicated treatment. Cell numbers were counted every 3 days. b, Mouse BFU-E cells were cultured in DEX 6 10 mM GW7647 as indicated. Total erythroid cell numbers were counted at day 9. c, Colony-forming assays were conducted to determine BFU-E colony numbers from 100 mouse BFU-E cells cultured under the indicated conditions. Colony-forming assays were performed at 24-h intervals. Data are mean 6 s.d. from three biological replicates; *P , 0.05, **P , 0.01, ***P , 0.001, Student's t-test. analysis to interrogate the genome-wide chromatin occupancy of GR and PPAR-a in mouse BFU-E cells. Compared to untreated cells, GR and PPAR-a occupancy were both induced upon DEX treatment alone; addition of GW7647 further enhanced PPAR-a but not GR occupancy ( Fig. 4a ). These results indicate that GW7647 enhances the recruitment of PPAR-a to GR-binding sites in BFU-Es. In BFU-Es co-treated with GW7647 and DEX, our ChIP-seq detected 1,058 GR and 1,623 PPAR-a peaks. GR and PPAR-a both predominantly occupied distal intergenic (.63%) and intronic chromatin sites (.25%) (Extended Data Fig. 6a ). Notably, in 719 peaks, GR and PPARa localize in close proximity (Extended Data Fig. 6b ); 67.9% of total GR peaks and 44.3% of PPAR-a peaks co-localize. The DNA sequences underlying these overlapping peaks are enriched for DNA-binding motifs for several transcription factors including PU.1, YY1, Smad3, Tal1, Klf4, Hif-2a and Myb (Extended Data Fig. 6c ); most of these transcription factors are known to have crucial roles in stem-cell selfrenewal 23 . In addition, co-treatment with DEX and GW7647 also upregulates many genes critical for stem-cell self-renewal (Supplementary Discussion and Extended Data Figs 7, 8) .
DEX treatment of BFU-E cells leads to a slight increase in PPAR-a protein levels, and this is further increased to 1.6 times that of control cells by treatment with DEX and GW7647 (Fig. 4c ). In contrast, the GR protein level is not altered in BFU-Es under these conditions. Consistent with these observations, addition of DEX to BFU-E cells induced the binding of both GR and PPAR-a to a chromatin site ,5 kb upstream of the transcription start site of Ppara, presumably part of a Ppara gene enhancer, and the binding of PPAR-a to this chromatin site was further enhanced by GW7647 addition (Fig. 4b ). Our data suggest that there is a positive autoregulatory feedback loop of PPAR-a expression during BFU-E self-renewal promoted by DEX and GW7647.
Co-immunoprecipitation experiments demonstrated an interaction of GR and PPAR-a only in BFU-E cells treated with DEX with or without GW7647 ( Fig. 4d ). While addition of DEX to cultures of BFU-E cells stimulated PPAR-a binding to the GR, interactions between PPAR-a and GR were more pronounced after treatment with both DEX and GW7647. These results extend our ChIP-seq data, indicating that there is a physical interaction between GR and PPAR-a and probably other proteins that underlies DEX-and GW7647-enhanced BFU-E selfrenewal (Supplementary Discussion and Extended Data Fig. 9 ).
Given that little is known concerning endogenous PPAR-a ligands, the precise role of PPAR-a in haematopoiesis, and erythropoiesis in particular, remains elusive. Nonetheless, our finding that agonists of PPAR-a lead to enhanced binding of PPAR-a to many chromatin sites and to an increase in corticosteroid-induced BFU-E self-renewal and erythroid expansion, point to a previously unappreciated role for this nuclear receptor in haematopoiesis (Extended Data Fig. 10 ). The function of PPAR-a has been mainly studied in nutrient metabolism and energy homeostasis, and fenofibrate is already an FDA-approved drug for dyslipidaemia treatment 18 . Given that there is a very limited number of drugs that can be used to treat Epo-resistant anaemias, the development of new drugs or repurposing current drugs to treat these diseases is challenging. Our surprising discovery suggests a novel function of PPAR-a in self-renewal of early committed erythroid progenitors, which could potentially lead to new therapeutics to treat Epo-resistant anaemias such as DBA. symptoms. a, Wild-type mice were pretreated with DMSO or 100 mg kg 21 GW7647 for 3 days (days 23 to 21) before PHZ injection on day 0. Mice were subject to daily DMSO or GW7647 injections during days 0-6. Haemoglobin (HGB), red blood cells (RBC) and haematocrit (HCT) were measured in wild-type mice on the days indicated. n 5 6. b, Nan/1 mutant mice were injected with DMSO or GW7647 (100 mg kg 21 ) for 18 days. Each dot represents one mouse. *P , 0.05, **P , 0.01, ***P , 0.001, Student's t-test. 
METHODS
Reagents. Chemicals were obtained from Sigma. Human peripheral blood granulocyte-colony stimulating factor (G-CSF)-mobilized haematopoietic stem/progenitor cells enriched for CD34 1 were purchased from the Fred Hutchinson Cancer Research Center (FHCRC). StemSpan SFEM, CC100 cytokine cocktail, fetal bovine serum and BSA were purchased from STEMCELL Technologies. Holo human transferrin was from Sigma. Recombinant human and murine stem cell factor (rhSCF, rmSCF) and interleukin-3 (rhIL-3, rmIL-3), recombinant murine interleukin-6 (rmIL-6) and recombinant murine insulin like growth factor-1 (rmIGF-1) were from Peprotech. Recombinant human erythropoietin (rhEpo) was from Amgen. Antibodies used were as follows. RPS19 shRNA is described in a previously published study 21 . Ex vivo human CD34 1 erythroid culture. Our human CD34 1 cell erythroid differentiation method is composed of 4 phases over 21 days: Expansion (day 0-4), differentiation (Dif) I (day 5-9), II (day 10-13), and III (day [14] [15] [16] [17] [18] [19] [20] [21] . Cells are thawed according to the FHCRC protocol, and cultured in expansion medium (StemSpan SFEM, CC100 cytokine cocktail and 2% penicillin-streptomycin) at 10 5 cells ml 21 from day 0 to 4. After expansion, cells are subsequently cultured in Iscove's modified Dulbecco's medium (IMDM)-based erythroid differentiation medium supplemented with different cytokines in Dif I, II and III. The medium base for all three differentiation phases comprises: IMDM, 15% FBS, 2 mM glutamine, 1% BSA, 500 mg ml 21 holo human transferrin, 10 mg ml 21 recombinant human insulin and 2% penicillin-streptomycin. On days 5-9, cells are cultured in Dif I medium, which contains erythroid medium base, 1 mM DEX, 1 mM b-oestradiol, 5 ng ml 21 rhIL-3, 100 ng ml 21 rhSCF and 6 U ml 21 rhEpo. On days 10-13, cells are grown in Dif II medium containing erythroid medium base, 50 ng ml 21 rhSCF and 6 U ml 21 rhEpo. On days 14-21, cells are cultured in fibronectincoated plates in Dif III medium, which is erythroid medium base supplemented with 2 U ml 21 rhEpo. GW7647 was added in both Dif I (100 nM) and Dif II (10 nM) when indicated. Cell numbers re-seeded in the beginning of Dif I, II and III were 10 5 , 2 3 10 5 , and 3 3 10 5 per ml, respectively. Mouse fetal liver BFU-E and CFU-E isolation and culture. Purification of BFU-E and CFU-E cells from murine fetal livers was performed as described previously 10 . Briefly, fetal liver erythroid cells were isolated between E14.5 and E15.5. A pure erythroid progenitor population containing more than 90% of BFU-E and CFU-E cells was obtained through a negative magnetic bead selection for lineage markers including Ter119, B220, Mac-1, CD3, Gr-1, Sca-1, CD16/ CD32, CD41, CD34 and positive selection for c-Kit. Afterwards c-Kit 1 BFU-E (CD71 10% low ) and CFU-E (CD71 20% high ) cells were separated by flow cytometry. Purified BFU-E or CFU-E cells were seeded in serum-free erythroid liquid expansion medium (SFELE) (StemSpan SFEM with 100 ng ml 21 rmSCF, 40 ng ml 21 rmIGF-1, and 2 U ml 21 rhEpo) alone, or SFELE containing 100 nM DEX 6 10 mM GW7647. Erythroblasts produced from purified BFU-E and CFU-E were analysed over time by FACS and benzidine-Giemsa staining as described 10 .
For Pu.1 knockdown, primary BFU-Es purified from mouse E14.5 fetal liver were incubated with virus encoding a shRNA for LacZ or mouse Pu.1 at 37 uC overnight. After incubation, cells were cultured in SFELE medium with or without DEX and/or GW7647. Colony-forming assay. Murine BFU-E colony-forming assays were performed in MethoCult M3234 (StemCell Technologies) containing 10 U ml 21 rhEpo, 20 ng ml 21 rmIL-3, 20 ng ml 21 rmIL-6 and 50 ng ml 21 rmSCF, with or without 100 nM DEX 6 10 mM GW7647. For CFU-E colony-forming assays, cells were cultured in MethoCult M3234 containing 10 U ml 21 rhEpo, with or without 100 nM DEX 6 10 mM GW7647. The number of CFU-E or BFU-E colonies was scored after 3 days or 7 days in culture, respectively.
For human colony-forming assays, cells were plated in MethoCult H4034 Optimum (StemCell Technologies) without additional cytokines. Cells were cultured for 12-14 days before BFU-E and CFU-E colonies were scored. In vivo mice experiments to test PPAR-a agonists. 129/SvImJ (wild-type), 129S4/SvJae (wild-type), or 129S4/SvJae-Ppara tm1Gonz /J female mice (The Jackson Laboratory), 6-8 weeks of age, randomized by weight, were pretreated with GW7647 (100 mg kg 21 ) for 3 days (days 23 to 21). On day 0, the mice were injected with phenylhydrazine (PHZ) (60 mg kg 21 ). GW7647 injection was continued during days 0-6. Whole blood samples were collected at each day of day 1-5, and day 7 and 9 for complete blood count (CBC) analyses.
Four-to six-week-old Nan/1 mutant mice (officially designated as Klf1 Nan ; http://www.informatics.jax.org/allele/MGI:1861107), obtained from the Jackson Laboratory, were injected with GW7647 (100 mg kg 21 ) for 18 days. Mice were randomized by weight. Whole blood samples were collected every 3 days for CBC analyses.
All mouse procedures were approved by the Animal Care and Use Committees of the Massachusetts Institute of Technology. Loss-of-function assay in human CD34 1 erythroid culture system
The lentiviral backbone vector pLKO.1 and packaging plasmids were transfected into 293T cells. Supernatants containing viral particles were harvested at 48 and 72 h. Primary human CD34 1 haematopoietic cells were transduced with lentivirus 1 day after thawing with the presence of 2 mg ml 21 polybrene (Sigma). Twenty four hours after viral transduction, cells were selected by growing in culture medium containing 1 mg ml 21 puromycin (Sigma) for 2 days.
For RPS19 knockdown, 5 3 10 5 CD34 cells at day 1 of culture were infected with lentivirus encoding GFP and a shRNA targeting human RPS19 (ref. 21) or a scrambled shRNA. Cells were then treated with DMSO or 0.01 mM, 0.1 mM or 1 mM GW7647. After 48 h, GFP-positive cells were isolated by flow cytometry and returned to culture. Colony-forming assays were conducted at day 6. CD71 expression was analysed at day 9 and CD235 expression was analysed at day 21 to determine the percentage of erythroid cells. Total cell numbers were also counted at the end of each differentiation stage. ChIP-seq and de novo motif discovery. Mouse ChIP-seq experiments in BFU-Es were conducted as described before 24 . 10 7 mouse BFU-E cells purified from E14.5 fetal liver with or without treatment were used per immunoprecipitation. Besides specific antibodies, we included species-matched IgG as control, and species-matched IgG yielded little to no signals. Purified DNA was prepared for sequencing according to a modified version of the Solexa genomic DNA protocol. ChIP-seq fragments as well as inputs were barcoded and sequenced on an Illumina HiSeq sequencer. Approximately 30 million 40-nucleotide-long single reads per sample were obtained. Adapters were removed and reads shorter than 20 nucleotides were discarded. Reads were mapped with Bowtie1 (ref. 25). Peaks were called with MACS 1.4 using the corresponding input for each sample and ''mfold'' set to 5,30 (ref. 26) . We selected peaks with fold enrichment $10. Plots showing density of reads around the peak summits were done with ngsplots. For de novo motif discovery, Homer was used with default setting to find motifs in GR and PPAR-a overlapping peaks 27 . RNA-seq. BFU-E cells from E14.5 mouse fetal livers were isolated as described 3 . Total RNA was purified from the mouse BFU-Es. Samples for paired-end mRNAseq were prepared using the Solexa kit according to the manufacturer's instructions. RNA samples from two replicas of cells untreated, or treated with DEX 6 GW7647 for 12 h were sequenced on an Illumina HiSeq sequencer. Around 50 million 100nucleotide paired-end reads were obtained from each sample. Reads were trimmed to remove low quality reads using FASTQ quality trimmer with a quality threshold of 20 (2t 20) and a minimum length to keep 25 nucleotides (2l 25). Reads that still had both pairs after the trimming step were mapped with TopHat 28 using gene models from ENSEMBL Genes 67, Mus musculus genes NCBIM37 (Mus_musculus.NCBIM37.67). The number of reads mapped to each gene was obtained with HTseq-count. Differential expression was assayed using DE-seq 29 .
For each of the 719 peaks bound by both GR and PPAR-a in the presence of GW7647 and DEX, we found the closest gene using the closestBed tool 30 . We filtered out any gene at a distance higher than 10 kb from a peak. Immunoprecipitation. Mouse BFU-Es were isolated from E14.5 mouse fetal livers. Cells were cultured in SFELE medium alone or treated with 100 nM DEX with or without 10 mM GW7647 for 12 h. Whole-cell lysates were prepared from 4 3 10 7 cells using RIPA lysis buffer (sc-24948, Santa Cruz Biotechnology) with protease inhibitor cocktail. The lysates were pre-cleared by incubating with protein A-Sepharose for 1 h at 4 uC and centrifugation. The supernatant was immunoprecipitated with 1 mg rabbit IgG or anti-GR antibody overnight at 4 uC. Immune complexes were collected by incubation with protein A-Sepharose for 4 h at 4 uC
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and washed five times at 4 uC with lysis buffer. The immune complexes adsorbed to the beads were centrifuged and the supernatant was removed. Fifty microlitres of 13 loading buffer was added to the samples and boiled at 95 uC for 5 min. Proteins were resolved by SDS-PAGE and immunoblotted by GR and PPAR-a antibodies. Quantitative real-time RT-PCR. Total RNA from mouse BFU-Es was purified with TRIzol (Invitrogen). cDNA was prepared from 1 mg RNA. Reaction mixtures (15 ml) contained 2.0 ml of cDNA, 7.5 ml of SYBR green master mix (Applied Biosystems) and appropriate primers. Product was monitored by SYBR green fluorescence. Control reactions lacking RT yielded little to no signal. Relative expression levels were determined from a DDC t method and were normalized to 18S rRNA expression. 
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Extended Data Figure 2 | Human CD34 1 erythroid differentiation system. a, Total CFU-E colonies formed during days 0-9. CFU-E colony numbers were quantified by plating 1,000 cells from various time points during days 0-9 of the human CD34 1 erythroid culture on methylcellulose. CFU-E colonies were quantified after 12-14 days. Total CFU-E colony numbers in culture under conditions without GW7647 (black line) or with GW7647 (red line) were calculated using the total cell numbers at corresponding time points in Fig. 2a . b, Human CD34 1 cells were treated at day 1 with 100 nM GW7647 with or without DEX at the concentration indicated in the figure. At day 6, total cell numbers were counted and cells were collected for BFU-E colony assays. c, Protein expression of PPAR-a demonstrating shRNA knockdown efficiency via lentiviral transduction. LacZ shRNA is used as a control. shRNA-1 and -2 are both specific for PPAR-a. shRNA-2 has higher knockdown efficiency. d, Cell pellets of 1 million cells demonstrating haemoglobin accumulation during the differentiation process. e, Flow cytometry analyses of erythroid Fig. 3a 
